| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Vogt Frederick G | Interim CEO & General Counsel, Director | C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 100, SAN CARLOS | /s/ Frederick G. Vogt | 03 Dec 2025 | 0001719678 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IOVA | Common Stock | Options Exercise | $0 | +41,669 | +9.6% | $0.000000 | 476,232 | 01 Dec 2025 | Direct | F1 |
| transaction | IOVA | Common Stock | Tax liability | $39,473 | -17,701 | -3.7% | $2.23 | 458,531 | 01 Dec 2025 | Direct | F2, F3 |
| transaction | IOVA | Common Stock | Options Exercise | $0 | +10,417 | +2.3% | $0.000000 | 468,948 | 02 Dec 2025 | Direct | F1 |
| transaction | IOVA | Common Stock | Tax liability | $9,472 | -4,426 | -0.94% | $2.14 | 464,522 | 02 Dec 2025 | Direct | F2, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IOVA | Restricted Stock Units | Options Exercise | $0 | -41,669 | -17% | $0.000000 | 208,344 | 01 Dec 2025 | Common stock | 41,669 | Direct | F4, F5, F6 | |
| transaction | IOVA | Restricted Stock Units | Options Exercise | $0 | -10,417 | -50% | $0.000000 | 10,418 | 02 Dec 2025 | Common stock | 10,417 | Direct | F4, F5, F7 |
| Id | Content |
|---|---|
| F1 | Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. |
| F2 | Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. |
| F3 | Represents common stock remaining after deducting the common stock withheld for taxes. |
| F4 | Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
| F5 | The remaining RSUs will vest in equal quarterly installments. |
| F6 | Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. |
| F7 | Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. |